# Corium International

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corium-international

- Industry: Biotechnology
- Headquarters: Grand Rapids, US
- Website: www.coriumgroup.com
- Total disclosed funding: $25M
- Latest round: Series D (Sep 26, 2007)
- Investors on record: 3

## About

Corium International, Inc. is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative transdermal and topical drug delivery systems.Founded in 1999 and headquartered in Grand Rapids, US, Corium International, Inc. develops advanced transdermal delivery systems. The company underwent a significant transition when it was acquired by Gurnet Point Capital in 2018, marking a shift from public to private ownership. Gary Cleary is noted as the founder, while Perry Sternberg serves as the current CEO. The company has engaged in a total of 5 funding rounds, with its most recent investment being a GROWTH round in April 2014, which raised USD 100.00 mn from Webster Equity Partners, matching the total amount raised since inception.Corium International focuses on developing advanced transdermal and topical drug delivery systems aimed at improving patient adherence and therapeutic outcomes. Their product lineup includes a range of innovative formulations that target various health conditions, leveraging proprietary technology to facilitate effective drug delivery. The company primarily serves the North American and global markets, positioning its offerings to meet a diverse array of healthcare needs.In the fiscal year 2017, Corium International reported a revenue of USD 31.86 mn. The company's financial performance also indicated an EBITDA loss of USD 37.97 mn for the same year, reflecting the investment in research and development activities in the biopharmaceutical sector.Corium International plans to utilize its recent funding to enhance its product development pipeline and explore new therapeutic areas. Future initiatives include launching new transdermal products aimed at unmet medical needs, with potential entry into new markets in Europe and Asia by the end of 2025. The funding received in April 2014 will support these strategic initiatives, focusing on expanding the company's footprint and developing innovative solutions for patients. The firm aims to strengthen its market position following its transition to private ownership, leveraging the financial backing from Gurnet Point Capital.

## Funding rounds

- Series D, Sep 26, 2007, $25M — Essex Woodlands, Aphelion Capital, Quantum Technology Partners

## Investors

- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series D
- Aphelion Capital (https://capitalatlas.ai/funds/aphelion-capital) — Series D
- Quantum Technology Partners (https://capitalatlas.ai/funds/quantum-technology-partners) — Series D